Johnson & Johnson Trying to Prevent Next Pandemic by Funding AVC Research

Biotech company Cidara is receiving up to $780 million from Johnson & Johnson in exchange for exclusive worldwide rights to the company's AVCs still in development. Jeffrey Stein, President and Chief Executive Officer of Cidara Therapeutics, joined Cheddar to discuss.
We use cookies and similar technologies on this site to collect identifiers, such as IP address, and cookie and device IDs as described in our Privacy Policy.